Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

7.23

Today's Change

+0.36 (5.24%)

Day's Change

6.86 - 7.27

Trading Volume

1,271,346

Overview

Market Cap

2 Billion

Shares Outstanding

315 Million

Avg Volume

1,536,247

Avg Price (50 Days)

6.16

Avg Price (200 Days)

3.80

PE Ratio

-45.19

EPS

-0.16

Earnings Announcement

22-Nov-2024

Previous Close

6.87

Open

7.05

Day's Range

6.86 - 7.27

Year Range

0.975 - 7.45

Trading Volume

1,271,346

Price Change Highlight

1 Day Change

5.24%

5 Day Change

-0.82%

1 Month Change

29.11%

3 Month Change

39.31%

6 Month Change

158.21%

Ytd Change

244.29%

1 Year Change

588.57%

3 Year Change

416.43%

5 Year Change

382.00%

10 Year Change

382.00%

Max Change

382.00%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment